WO2019215759A1 - Procédé amélioré de préparation de midostaurine - Google Patents

Procédé amélioré de préparation de midostaurine Download PDF

Info

Publication number
WO2019215759A1
WO2019215759A1 PCT/IN2019/050369 IN2019050369W WO2019215759A1 WO 2019215759 A1 WO2019215759 A1 WO 2019215759A1 IN 2019050369 W IN2019050369 W IN 2019050369W WO 2019215759 A1 WO2019215759 A1 WO 2019215759A1
Authority
WO
WIPO (PCT)
Prior art keywords
midostaurin
solvent
process according
preparation
staurosporine
Prior art date
Application number
PCT/IN2019/050369
Other languages
English (en)
Inventor
Lakshmi Prasad ALAPARTHI
Ginjupalli Sadasiva RAO
Original Assignee
Alaparthi Lakshmi Prasad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alaparthi Lakshmi Prasad filed Critical Alaparthi Lakshmi Prasad
Publication of WO2019215759A1 publication Critical patent/WO2019215759A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Definitions

  • the present invention relates to a novel process for preparation of Midostaurin of formula I.
  • Midostaurin is N-[(9S,l0R,l lR,l3R)-2,3,l0,l l,l2,l3-hexahydro-l0-methoxy-9- methyl-l-oxo-9,l3-epoxy-lH,9H-diindolo[l,2,3-gh:3',2',l '-lm]pyrrolo[3,4-j][l,7] benzodiazonin-l l-yl] -N-methylbenzamide of the following formula:
  • the drug Midostaurin is used as an anti-tumour agent.
  • the preparation of Midostaurin is disclosed in U.S. Patent No. 5,093,330.
  • efficient, and industrially viable process of preparation the Midostaurin is certain important. Therefore, there is a continuing need for new process of preparation of Midostaurin.
  • Staurosporine the basic element of the derivatives according to the present invention was isolated already in the year 1977 from cultures of Streptomyces staurosporeus AWAYA, TAKAHASHI and OMURA, sp. nov. AM 2282, cf. S. Omura et al., J. Antibiot. 30, 275-281 (1977). Hitherto, only the relative, but not the absolute configuration of staurosporin was known. The absolute configuration was published only recently by N. Funato et al., Tetrahedron Letters 35:8, 1251-1254 (1994) and corresponds to the mirror image of the structure, used up to now in the literature to denote the relative configuration of staurosporine.
  • U.S. Patent No. 5,093,330 discloses N-benzoyl-staurosporine.
  • the invention relates especially to a particular N-benzoyl-staurosporine derivative of the compound.
  • the U.S. Patent No. 5,093,330 discloses in Example 18 process for the preparation of N- benzoyl-staurosporine derivative (Midostaurin) by reacting staurosporine with benzoyl chloride at room temperature in presences of N,N-diisopropylethylamine and chloroform. This process requires anhydrous conditions as benzoyl chloride gets converted to benzoic acid and the reaction doesn’t proceed to completion. Moreover it is observed that more impurities are formed in this reaction.
  • EP2272850B1 discloses process for the preparation of crystalline form II of N-benzoyl-staurosporine.
  • the invention relates especially to a particular crystalline form II of N-benzoyl-staurosporine of the compound.
  • the European Patent No. EP2272850B1 discloses process for the preparation of N- benzoyl-staurosporine by reacting purified staurosporine in an alcohol solvent with benzoic anhydride. This process requires longer reaction times to proceed for reaction completion.
  • the present invention is directed to provide novel process for the preparation of Midostaurin of formula I which is efficient, industrially viable wherein reaction conditions are mild and simple for operation, less expensive cost effective process.
  • of the present invention is to provide an improved process for the preparation of N-[(9S,l0R,l lR,l3R)-2,3,l0,l l,l2,l3-hexahydro-l0- methoxy-9 -methyl- 1 -oxo-9, l3-epoxy- lH,9H-diindolo[ 1 ,2,3-gh:3 ',2', 1 '- lm]pyrrolo[3,4-j][l,7] benzodiazonin-l l-yl] -N-methylbenzamide (Midostaurin) of formula I and pharmaceutically acceptable salts thereof.
  • of the present invention is to provide improved process for the preparation of Midostaurin by reacting staurosporine with benzoic acid.
  • of the present invention is to provide improved process for the purifying of Midostaurin by treating with solvent and anti- solvent precipitation process.
  • the term“pharmaceutically acceptable salt” refers to those salts which are suitable for pharmaceutical use, preferably for use in the tissues of humans and lower animals without undue irritation, allergic response and the like.
  • Pharmaceutically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art. For example, S. M. Berge, et al., describe pharmaceutically acceptable salts in detail in J Pharmaceutical Sciences, 66: 1-19 (1977), incorporated herein by reference.
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting a free base or free acid function with a suitable reagent, as described generally below. For example, a free base function can be reacted with a suitable acid.
  • suitable pharmaceutically acceptable salts thereof may, include metal salts such as alkali metal salts, e. g. sodium or potassium salts; and alkaline earth metal salts, e. g. calcium or magnesium salts.
  • suitable pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hernisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methane sulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pectinate, persulfate, 3- phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succ
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed by direct reaction with the drug carboxylic acid or by using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate and aryl sulfonate.
  • purified refers to a compound that has been processed to remove impurities. Impurities can include solvents, reagents used to prepare the compound, starting materials, and byproducts of a reaction giving rise to the compound. In some embodiments, a purified compound is substantially free of other species.
  • crude compound refers to a mixture containing a desired compound (such as a compound of Formula I as described herein) and at least one other species selected from a solvent, a reagent such as a base, a starting material, and a byproduct of a reaction giving rise to the desired compound.
  • a desired compound such as a compound of Formula I as described herein
  • a reagent such as a base, a starting material, and a byproduct of a reaction giving rise to the desired compound.
  • Anti-solvent is a solvent which when added to an existing solution of a substance reduced the solubility of the substance.
  • the terms “treating”, “contacting” and “reacting” are used interchangeably herein and refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or desired product. It should be appreciated that the reaction which produces the indicated and/or desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or desired product.
  • the present invention provides process for preparation of Midostaurin compound of formula I which comprising: (i) reacting the staurosporine with benzoic acid in presence of condensing agent and solvent;
  • said condensing agent is selected from the group consisting of 2-( 1 H-benzotriazol- 1 -y 1) - 1 , 1 ,3 ,3-tetramethyluronium hexafluorophosphate (HBTU) /N-Hydroxybenzotriazole (HOBt) / Diisopropylethylamine(DIPEA)
  • product Midostaurin may be further purified or washed with the solvent multiple times to produce Midostaurin essentially free of impurites.
  • the solvent is selected from but not limited to polar aprotic solvents are N-Methyl-2-pyrrolidone (NMP), Dichloromethane (DCM), Tetrahydrofuran (THF), Ethyl acetate (EtOAc), Acetone, Dimethylformamide (DMF), Acetonitrile (MeCN), Dimethyl sulfoxide (DMSO), Dimethylacetamide; N,N-Diisopropyl ethylamine, dioxane, tetrahydrofuran, acetone, hexane, benzene, toluene, l,4-dioxane, chloroform, diethyl ether, n-butanol, isopropanol, n-propanol, ethanol, methanol, water, water, alcohols, ketones, diols, triols, esters, amides, ethers, hydrocarbons, sulf
  • the solvent can be any liquid in which the Midostaurin crude dissolves wherein the solvent can be a mixture of co-solvents the important point being that the solution of Midostaurin crude to be treated with another solvent or a mixture of co-solvents as anti-solvent.
  • Solvents useful in the invention include materials that are liquid at room temperature, dissolve the material.
  • the crude Midostaurin is dissolved in an amount of first solvent sufficient to dissolve the Midostaurin.
  • the resulting Midostaurin solution is heated to about the boiling point of the first solvent.
  • the addition of the second solvent, or anti-solvent takes place, with the addition of the second solvent or anti-solvent being added in an amount sufficient to precipitating Midostaurin from the solvents.
  • the precipitation step comprises cooling the Midostaurin solution to room temperature sufficient to bring about Midostaurin. Most preferably the temperature sufficient for precipitation of Midostaurin is about 25°C.
  • first solvent: second solvent or anti-solvent system combination is IPA : water.
  • Example-2 Process for preparation of Midostaurin Prepared a solution of benzoic acid (50 mg; 0.4 mmol) and HBTU (170 mg; 0.45 mmol) in DMF. Added N,N-Diisopropyl ethyalmine (220 mL; 1.3 mmol). Stirred the mixture for 90 minutes at 25°C, charged staurosporine (600 mg; 1.3 mmol) to the reaction mixture. Stirred the reaction mixture for 4 hours. The reaction mass is diluted with water followed by extraction with ethyl acetate. The organic layer is dried over sodium sulphate and distilled under vacuum to get residue. Triturated the residue with ether. The solid obtained is filtered and dried to get Midostaurin. (Yield: 70%; purity by HPLC: 88%). The obtained solid is eluted with ethyl acetate and dichloromethane system to get Midostaurin with purity >97% by HPLC.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un procédé de préparation de midostaurine. Plus particulièrement, l'invention concerne un procédé de préparation de midostaurine consistant à faire réagir la staurosporine avec de l'acide benzoïque en présence d'agent de condensation. Dans un aspect de l'invention, un nouveau procédé de purification de midostaurine est décrit.
PCT/IN2019/050369 2018-05-09 2019-05-09 Procédé amélioré de préparation de midostaurine WO2019215759A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821017401 2018-05-09
IN201821017401 2018-05-09

Publications (1)

Publication Number Publication Date
WO2019215759A1 true WO2019215759A1 (fr) 2019-11-14

Family

ID=68467858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2019/050369 WO2019215759A1 (fr) 2018-05-09 2019-05-09 Procédé amélioré de préparation de midostaurine

Country Status (1)

Country Link
WO (1) WO2019215759A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN112812129A (zh) * 2020-12-31 2021-05-18 浙江海正药业股份有限公司 米哚妥林的新晶型及其制备方法和用途
WO2022199576A1 (fr) * 2021-03-24 2022-09-29 扬州联澳生物医药有限公司 Procédé de préparation de midostaurine de haute pureté
WO2022243679A2 (fr) 2021-05-18 2022-11-24 Kinomica Limited Méthodes et kits pour prédire l'efficacité de la midostaurine pour le traitement du cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296110A2 (fr) * 1987-06-15 1988-12-21 Ciba-Geigy Ag Dérivés de staurosporine substitués à l'azote du méthylamino
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1993007153A1 (fr) * 1991-10-10 1993-04-15 Schering Corporation Derives de staurosporine 4'-(n-substituee-n-oxydee)
US8198435B2 (en) * 2004-11-05 2012-06-12 Novartis Ag Crystal form of N-benzoyl-staurosporine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296110A2 (fr) * 1987-06-15 1988-12-21 Ciba-Geigy Ag Dérivés de staurosporine substitués à l'azote du méthylamino
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1993007153A1 (fr) * 1991-10-10 1993-04-15 Schering Corporation Derives de staurosporine 4'-(n-substituee-n-oxydee)
US8198435B2 (en) * 2004-11-05 2012-06-12 Novartis Ag Crystal form of N-benzoyl-staurosporine

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN112812129A (zh) * 2020-12-31 2021-05-18 浙江海正药业股份有限公司 米哚妥林的新晶型及其制备方法和用途
WO2022142914A1 (fr) * 2020-12-31 2022-07-07 浙江海正药业股份有限公司 Nouvelle forme cristalline de midostaurine, son procédé de préparation et son utilisation
WO2022199576A1 (fr) * 2021-03-24 2022-09-29 扬州联澳生物医药有限公司 Procédé de préparation de midostaurine de haute pureté
CN115124551A (zh) * 2021-03-24 2022-09-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2022243679A2 (fr) 2021-05-18 2022-11-24 Kinomica Limited Méthodes et kits pour prédire l'efficacité de la midostaurine pour le traitement du cancer

Similar Documents

Publication Publication Date Title
WO2019215759A1 (fr) Procédé amélioré de préparation de midostaurine
EP0283055B1 (fr) Dérivés de 10-dihydro-10-déoxo-11-azaérythronolide-A, procédés et intermédiaires pour leur préparation et leur utilisation dans et pour la préparation de médicaments
JP3998828B2 (ja) 新規なエリスロマイシン誘導体、それらの製造法及び薬剤としての使用
JPS6328438B2 (fr)
JP2000229993A (ja) 新規のエリスロマイシン誘導体、それらの製造方法及びそれらの薬剤としての使用
WO2019135254A1 (fr) Polymorphes d'apalutamide et leur préparation
EP4046687A1 (fr) Procédé de production de la centanafadine
US11939342B2 (en) Process for the preparation of midostaurin with high purity
CA2960473A1 (fr) Procedes de preparation de tadalafil et d'intermediaires associes
WO2011153221A1 (fr) Formes d'ixabepilone à l'état solide
IT201800003284A1 (it) Forme cristalline di venetoclax
EP1590353B1 (fr) Procede pour preparer du cefpodoxime proxetil
KR20070099034A (ko) 타달라필의 정제 방법
CN111808040B (zh) 多构型2-氧代噁唑烷-4-羧酸类化合物的合成方法
WO2020049598A2 (fr) Polymorphes d'apalutamide
US20060247427A1 (en) Process to obtain 6-O-methylerythromycin a (clarithromycin)_form II
CN114685479B (zh) 噁唑烷酮类化合物及其制备方法和应用
CN111233857B (zh) 一种连续化生产培西达替尼的合成方法
WO2008035189A1 (fr) Procédé de purification du lansoprazole
WO2007112473A1 (fr) Purification d'un anomère de difluoronucléoside au moyen d'une solution acide aqueuse
JP2023500897A (ja) 実質的に純粋なクラリスロマイシン ９－オキシム（Ｃｌａｒｉｔｈｒｏｍｙｃｉｎ ９－ｏｘｉｍｅ）及びその調製
JPS6152839B2 (fr)
WO2006010978A1 (fr) Formes polymorphes de cefdinir, et son sel d'imidazole
JPH051053A (ja) ６−（３−ジメチルアミノプロピオニル）フオルスコリンの新規製造法
JP2935515B2 (ja) １―アザビシクロ［ｍ，ｎ，０］アルカン誘導体及びその塩並びにこれらの製法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19800851

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19800851

Country of ref document: EP

Kind code of ref document: A1